- form
- 8-K
- rationale
- The release states 2024 EPS guidance was 'lowered to the ranges of $12.05 to $12.55 on a reported basis' from a prior range of '$15.10 to $15.60', while Q3 2024 reported EPS of $1.07 itself was not compared to prior Lilly guidance in the text—guidance was revised due to Q3 IPR&D charges rather than results beating/missing a stated prior quarterly forecast, but revenue guidance was 'updated to between $45.4 billion and $46.0 billion' with Q3 revenue of $11.44 billion contributing to a narrowed range, indicating results trending at the upper end of prior full-year revenue guidance of '$45.4 to $46.6 billion'.
- vs_guidance
- above
- source_document
- q324lillysalesandearningsp.htm
- accession_number
- 0000059478-24-000242
- extraction_confidence
- 0.85